Chi Sheng Pharma & Biotech Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2020
March 25, 2021 at 05:54 pm
Share
Chi Sheng Pharma & Biotech Co. Ltd. announced earnings results for the full year ended December 31, 2020. For the full year, the company announced total revenue was TWD 979.359 million compared to TWD 1,022.956 million a year ago. Operating income was TWD 75.553 million compared to TWD 87.265 million a year ago. Net income was TWD 59.141 million compared to TWD 72.450 million a year ago. Basic earnings per share was TWD 1.04 compared to TWD 1.27 a year ago. Diluted earnings per share was TWD 1.03 compared to TWD 1.27 a year ago.
Chi Sheng Pharma & Biotech Co., Ltd, formerly Chi Sheng Chemical Corporation is principally engaged in the manufacture and distribution of general medicines and medicinal injections. The Company provides injections, including hemodialysis concentrate, amino acid injection with electrolytes, vitamins, cephalosporin antibiotics, antihistamines and antipruritics, as well as ginkgo injections; oral preparations, including antibiotics, cold syrups and liquid antacid; external medicines, including contact lens fluid, normal saline for wash and povidone-iodine solution, and consumer goods, including functional health foods, skin care products and cosmetics. It also provides medical devices and equipment. The Company distributes its products in domestic markets and to overseas markets, including Mainland China and Southeast Asia.
CHI SHENG PHARMA & BIOTECH CO., LTD 
